Lamivudina Viatris

Lamivudine, the active ingredient in Lamivudina Viatris, is a nucleoside reverse transcriptase inhibitor (NRTI) presented as an oral tablet for oral use. It is employed in the management of Human Immunodeficiency Virus (HIV) infection and chronic hepatitis B infection in adult patients. The medication is formulated according to European Union standards and is supplied under a prescription‑only designation.

GNH USA supplies Lamivudina Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our network ensures reliable delivery and regulatory compliance across multiple regions.

Lamivudine is used as an antiretroviral agent targeting viral replication in specific infections. - Human Immunodeficiency Virus (HIV) infection: reduces viral load and helps restore immune function. - Chronic hepatitis B virus (HBV) infection: suppresses viral replication and improves liver enzyme levels. - Mother‑to‑child transmission of HIV (when used in combination therapy): lowers the risk of vertical transmission during pregnancy and delivery. - HIV/HBV co‑infection: provides dual antiviral activity to control both viruses simultaneously.

Lamivudine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild stomach upset. - Headache: transient headache. - Diarrhea: loose stools.

Serious or Rare Side Effects: - Lactic acidosis: rare metabolic disturbance. - Severe hepatotoxicity: significant liver injury. - Stevens‑Johnson syndrome: severe skin reaction.

Lamivudine requires careful monitoring and patient counseling to minimize risks. - Liver function monitoring: assess hepatic enzymes before and during therapy. - Renal function assessment: adjust use in patients with impaired kidney function. - Adherence counseling: emphasize consistent dosing to prevent resistance. - Drug interaction review: avoid concurrent use with didanosine or stavudine. - Pregnancy considerations: weigh potential benefits against unknown risks. - Store at room temperature: keep in original container, protect from moisture and light.

Lamivudine can interact with several medicines, necessitating review of concomitant therapies.

Major Interactions (Avoid): - Didanosine: increased risk of pancreatitis. - Stavudine: heightened peripheral neuropathy risk. - Other NRTIs (e.g., zidovudine) in high doses: potential mitochondrial toxicity.

Moderate Interactions (Monitor Closely): - Alcohol: may exacerbate liver toxicity. - Nephrotoxic agents (e.g., tenofovir): monitor renal function. - Certain antiretroviral boosters (e.g., ritonavir): may alter lamivudine levels.